Anika Therapeutics (ANIK) Expected to Release Earnings on Wednesday

Anika Therapeutics (NASDAQ:ANIK) will likely be announcing its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to announce earnings of $0.03 per share and revenue of $29.2140 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:30 AM ET.

Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $0.27 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.34. The business had revenue of $29.61 million during the quarter, compared to the consensus estimate of $28.14 million. Anika Therapeutics had a negative net margin of 9.52% and a negative return on equity of 5.90%. On average, analysts expect Anika Therapeutics to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Anika Therapeutics Trading Up 0.5%

NASDAQ:ANIK opened at $15.02 on Tuesday. The firm has a market cap of $199.92 million, a PE ratio of -19.01 and a beta of 0.23. The stock has a fifty day moving average price of $14.98 and a 200 day moving average price of $13.57. Anika Therapeutics has a 12-month low of $7.87 and a 12-month high of $16.49.

Insiders Place Their Bets

In other news, Director John B. Henneman III bought 5,000 shares of Anika Therapeutics stock in a transaction dated Friday, May 1st. The stock was acquired at an average cost of $14.66 per share, with a total value of $73,300.00. Following the acquisition, the director owned 54,871 shares of the company’s stock, valued at approximately $804,408.86. This trade represents a 10.03% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Stephen D. Griffin purchased 12,200 shares of the business’s stock in a transaction on Thursday, April 30th. The shares were purchased at an average cost of $12.29 per share, for a total transaction of $149,938.00. Following the transaction, the chief executive officer owned 36,163 shares of the company’s stock, valued at $444,443.27. This trade represents a 50.91% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 12.08% of the stock is owned by insiders.

Hedge Funds Weigh In On Anika Therapeutics

Institutional investors have recently modified their holdings of the business. Ameriprise Financial Inc. boosted its stake in Anika Therapeutics by 4.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 41,362 shares of the biotechnology company’s stock worth $438,000 after purchasing an additional 1,820 shares during the period. Quadrature Capital Ltd acquired a new stake in shares of Anika Therapeutics during the fourth quarter worth about $430,000. Engineers Gate Manager LP grew its holdings in shares of Anika Therapeutics by 66.9% during the fourth quarter. Engineers Gate Manager LP now owns 40,276 shares of the biotechnology company’s stock worth $387,000 after buying an additional 16,150 shares during the last quarter. Cerity Partners LLC grew its holdings in shares of Anika Therapeutics by 5.2% during the fourth quarter. Cerity Partners LLC now owns 31,775 shares of the biotechnology company’s stock worth $305,000 after buying an additional 1,575 shares during the last quarter. Finally, Occudo Quantitative Strategies LP increased its position in Anika Therapeutics by 152.5% in the 4th quarter. Occudo Quantitative Strategies LP now owns 25,510 shares of the biotechnology company’s stock valued at $245,000 after acquiring an additional 15,407 shares during the period. 91.53% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Wall Street Zen lowered Anika Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Anika Therapeutics in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Anika Therapeutics currently has an average rating of “Hold” and a consensus target price of $17.00.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.